Mucopolysaccharidosis Type II
Co-Pay Relief Program Fund Notices
Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!
Approved and Donation Ready
This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.
If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.
Fund TypeCo-Pay, Co-insurance & Deductible (medications and office visits)
Maximum Award Level$8,000
- Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
- Insurance Requirements All Insurance Types
- Must reside and receive treatment in the United States.
About Mucopolysaccharidosis Type II
Mucopolysaccharidosis II (MPS II) is an inherited disorder of carbohydrate metabolism that occurs almost exclusively in males. It is characterized by distinctive facial features, a large head, hydrocephalus, enlargement of the liver and spleen (hepatosplenomegaly), umbilical or inguinal hernia, and hearing loss. Individuals with this condition may additionally have joint deformities and heart abnormalities involving the valves. MPS II is caused by mutations in the IDS gene and is inherited in an X-linked manner. People born with MPS Type II are missing the enzyme iduronate sulfatase, which is essential to breaking down the mucopolysaccharides dermatan and heparan sulphate. These materials remain stored in the body’s cells, causing progressive damage. There are two types of MPS II, slowly progressive and early progressive. People with severe MPS II experience a decline in intellectual functioning and a more rapid disease progression. This is a rare condition affecting 1 in 100,000 to 1 in 170,000 primarily males. Other names for this condition include: Hunter syndrome, IS2 deficiency, Iduronate 2-sulfatase deficiency, and MPS II.
- CancerCare866-55-COPAY
- Good Days877-968-7233
- Healthwell Foundation800-675-8416
- National Organization for Rare Disorders800-999-6673
- Needy Meds800-503-6897
- Patient Access Network Foundation866-316-7263
- Patient Services Inc.800-366-7741
- The Assistance Fund855-845-3663
